Literature DB >> 28101798

miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.

Insaf Fkih M'hamed1,2,3, Maud Privat1,2, Mounir Trimeche4, Frédérique Penault-Llorca2, Yves-Jean Bignon1,2, Abderraouf Kenani5.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs composed of 18-25 nucleotides that can post-transcriptionally regulate gene expression and have key regulatory roles in cancer, acting as both oncogenes and tumor suppressors. About 1000 genes in humans encode miRNAs, which account for approximately 3% of the human genome, and up to 30% of human protein coding genes may be regulated by miRNAs. The objective of this article is to evaluate the expression profile of four miRNAs previously implicated in triple negative breast cancer: miR-10b, miR-26a, miR-146a and miR-153, and to determine their possible interaction in triple negative and non triple negative breast cancer based on clinical outcome and the expression of BRCA1. 24 triple-negative and 13 non triple negative breast cancer cases, were studied by q-RT-PCR and immunohistochemistry to determine the expression of the four studied miRNAs and the BRCA1 protein, respectively. We observed that the BRCA1 protein was absent in 62.5% of the triple negative cases. Besides, the miR-146a and miR-26a were over expressed in triple negative breast cancer. These two miRNAs, miR-10b and miR-153 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma. All the analyzed microRNAs were not associated with the expression of BRCA1 in our conditions. Our work provides evidence that miR-146a, miR-26a, miR-10b and miR-153 could be defined as biomarkers in triple negative breast cancer to predict lymph node metastases (LNM).

Entities:  

Keywords:  Biomarkers; Human triple negative breast cancer; LNM; MicroRNAs

Mesh:

Substances:

Year:  2017        PMID: 28101798     DOI: 10.1007/s12253-017-0188-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  41 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  miRNA - Therapeutic tool in breast cancer? Where are we now?

Authors:  Karolina Zaleska
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-26

3.  The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers.

Authors:  Weijie Chen; Fengfeng Cai; Bei Zhang; Zeinab Barekati; Xiao Yan Zhong
Journal:  Tumour Biol       Date:  2012-12-14

4.  Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.

Authors:  Nami Yamashita; Eriko Tokunaga; Hiroyuki Kitao; Megan Hitchins; Yuka Inoue; Kimihiro Tanaka; Yuichi Hisamatsu; Kenji Taketani; Sayuri Akiyoshi; Satoko Okada; Yoshinao Oda; Hiroshi Saeki; Eiji Oki; Yoshihiko Maehara
Journal:  Clin Breast Cancer       Date:  2015-06-18       Impact factor: 3.225

5.  MicroRNA-153 expression and prognosis in non-small cell lung cancer.

Authors:  Wei-Jun Chen; En-Ning Zhang; Zhao-Kun Zhong; Mao-Zhu Jiang; Xi-Feng Yang; Dong-Mei Zhou; Xiu-Wen Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 6.  MicroRNAs as regulatory elements in triple negative breast cancer.

Authors:  Melina-Theoni Gyparaki; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Cancer Lett       Date:  2014-08-10       Impact factor: 8.679

7.  Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.

Authors:  Zhuo-Jia Chen; Wei Wei; Guan-Min Jiang; Hao Liu; Wei-Dong Wei; Xiangling Yang; Ying-Min Wu; Huanliang Liu; Chris K C Wong; Jun Du; Hong-Sheng Wang
Journal:  Mol Oncol       Date:  2016-01-18       Impact factor: 6.603

8.  Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.

Authors:  Isabel Stückrath; Brigitte Rack; Wolfgang Janni; Bernadette Jäger; Klaus Pantel; Heidi Schwarzenbach
Journal:  Oncotarget       Date:  2015-05-30

Review 9.  The complexity of microRNAs in human cancer.

Authors:  Jennifer Y Y Kwan; Pamela Psarianos; Jeff P Bruce; Kenneth W Yip; Fei-Fei Liu
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

10.  Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer.

Authors:  Jingdan Qiu; Xinying Xue; Chao Hu; Hu Xu; Deqiang Kou; Rong Li; Ming Li
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

View more
  12 in total

1.  MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression.

Authors:  Zhi-Xue Yang; Bo Zhang; Jinrong Wei; Guo-Qin Jiang; Yan-Lin Wu; Bing-Jing Leng; Chun-Gen Xing
Journal:  Cancer Cell Int       Date:  2018-01-30       Impact factor: 5.722

2.  KCNQ1OT1 promotes melanoma growth and metastasis.

Authors:  Bingyu Guo; Qian Zhang; Hongyi Wang; Peng Chang; Kai Tao
Journal:  Aging (Albany NY)       Date:  2018-04-17       Impact factor: 5.682

Review 3.  MicroRNAs in regulation of triple-negative breast cancer progression.

Authors:  Dominika Piasecka; Marcin Braun; Radzislaw Kordek; Rafal Sadej; Hanna Romanska
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-19       Impact factor: 4.553

4.  Upregulation Of miR-153 Inhibits Triple-Negative Breast Cancer Progression By Targeting ZEB2-Mediated EMT And Contributes To Better Prognosis.

Authors:  Dongliang Shi; Yong Li; Liqiao Fan; Qun Zhao; Bibo Tan; Guozhong Cui
Journal:  Onco Targets Ther       Date:  2019-11-13       Impact factor: 4.147

Review 5.  MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.

Authors:  Mohammad Mijanur Rahman; Andrew C Brane; Trygve O Tollefsbol
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

Review 6.  MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.

Authors:  Simona Ruxandra Volovat; Constantin Volovat; Irina Hordila; Dorin-Alexandru Hordila; Ciprian Camil Mirestean; Oana Tatiana Miron; Cristian Lungulescu; Dragos Viorel Scripcariu; Cati Raluca Stolniceanu; Assia Adrianova Konsoulova-Kirova; Cristina Grigorescu; Cipriana Stefanescu; Cristian Constantin Volovat; Iolanda Augustin
Journal:  Front Oncol       Date:  2020-11-20       Impact factor: 6.244

Review 7.  The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.

Authors:  Getinet M Adinew; Equar Taka; Patricia Mendonca; Samia S Messeha; Karam F A Soliman
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

8.  Changes in circulating microRNA levels can be identified as early as day 8 of pregnancy in cattle.

Authors:  Jason Ioannidis; F Xavier Donadeu
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

9.  A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.

Authors:  Hsiao-Chin Hong; Cheng-Hsun Chuang; Wei-Chih Huang; Shun-Long Weng; Chia-Hung Chen; Kuang-Hsin Chang; Kuang-Wen Liao; Hsien-Da Huang
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

10.  Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.

Authors:  Elena Alexandrova; Jessica Lamberti; Pasquale Saggese; Giovanni Pecoraro; Domenico Memoli; Valeria Mirici Cappa; Maria Ravo; Roberta Iorio; Roberta Tarallo; Francesca Rizzo; Francesca Collina; Monica Cantile; Maurizio Di Bonito; Gerardo Botti; Giovanni Nassa; Alessandro Weisz; Giorgio Giurato
Journal:  Cells       Date:  2020-04-03       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.